Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Assets (2022 - 2025)

Stoke Therapeutics has reported Assets over the past 4 years, most recently at $418.4 million for Q4 2025.

  • Quarterly results put Assets at $418.4 million for Q4 2025, up 54.09% from a year ago — trailing twelve months through Dec 2025 was $418.4 million (up 54.09% YoY), and the annual figure for FY2025 was $418.4 million, up 54.09%.
  • Assets for Q4 2025 was $418.4 million at Stoke Therapeutics, up from $360.3 million in the prior quarter.
  • Over the last five years, Assets for STOK hit a ceiling of $418.4 million in Q4 2025 and a floor of $205.2 million in Q1 2024.
  • Median Assets over the past 4 years was $287.6 million (2023), compared with a mean of $300.4 million.
  • Biggest five-year swings in Assets: dropped 27.19% in 2024 and later soared 98.31% in 2025.
  • Stoke Therapeutics' Assets stood at $256.1 million in 2022, then fell by 10.83% to $228.3 million in 2023, then grew by 18.92% to $271.6 million in 2024, then soared by 54.09% to $418.4 million in 2025.
  • The last three reported values for Assets were $418.4 million (Q4 2025), $360.3 million (Q3 2025), and $384.5 million (Q2 2025) per Business Quant data.